S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:GNMKGenMark Diagnostics Stock Price, Forecast & News

$15.10
-0.37 (-2.39 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.71
Now: $15.10
$15.55
50-Day Range
$13.33
MA: $16.62
$19.10
52-Week Range
$3.36
Now: $15.10
$20.88
Volume1.49 million shs
Average Volume2.25 million shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.07
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Read More
GenMark Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$88.02 million
Book Value$0.21 per share

Profitability

Net Income$-47,350,000.00

Miscellaneous

Employees477
Market Cap$1.07 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$15.10
-0.37 (-2.39 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

How has GenMark Diagnostics' stock been impacted by Coronavirus (COVID-19)?

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNMK shares have increased by 178.6% and is now trading at $15.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GenMark Diagnostics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GenMark Diagnostics
.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for GenMark Diagnostics
.

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings data on Tuesday, August, 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.03. GenMark Diagnostics had a negative return on equity of 93.75% and a negative net margin of 26.51%.
View GenMark Diagnostics' earnings history
.

What guidance has GenMark Diagnostics issued on next quarter's earnings?

GenMark Diagnostics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155-165 million, compared to the consensus revenue estimate of $127.89 million.

What price target have analysts set for GNMK?

6 Wall Street analysts have issued 12 month price targets for GenMark Diagnostics' shares. Their forecasts range from $7.00 to $22.00. On average, they expect GenMark Diagnostics' stock price to reach $16.80 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for GenMark Diagnostics
.

Has GenMark Diagnostics been receiving favorable news coverage?

News stories about GNMK stock have trended negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GenMark Diagnostics earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near future.
View the latest news about GenMark Diagnostics
.

Are investors shorting GenMark Diagnostics?

GenMark Diagnostics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,900,000 shares, a decline of 22.7% from the April 30th total of 3,750,000 shares. Based on an average daily volume of 3,640,000 shares, the short-interest ratio is presently 0.8 days.
View GenMark Diagnostics' Short Interest
.

Who are some of GenMark Diagnostics' key competitors?

What other stocks do shareholders of GenMark Diagnostics own?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the following people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 58)
  • Mr. Scott Mendel, Chief Operating Officer (Age 52)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
  • Mr. John Frederick Ek, Chief Financial Officer (Age 43)
  • Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (1.86%), Wasatch Advisors Inc. (1.80%), HighTower Advisors LLC (1.37%), Goldman Sachs Group Inc. (1.32%), William Blair Investment Management LLC (0.89%) and Cowen Prime Services LLC (0.70%). Company insiders that own GenMark Diagnostics stock include Alan Baer Maderazo, Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel and Tyler Jensen.
View institutional ownership trends for GenMark Diagnostics
.

Which major investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Granite Investment Partners LLC, Envestnet Asset Management Inc., Essex Investment Management Co. LLC, OLD National Bancorp IN, Commonwealth Equity Services LLC, Dupont Capital Management Corp, and UBS Group AG. Company insiders that have sold GenMark Diagnostics company stock in the last year include Alan Baer Maderazo, Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel, and Tyler Jensen.
View insider buying and selling activity for GenMark Diagnostics
.

Which major investors are buying GenMark Diagnostics stock?

GNMK stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Wasatch Advisors Inc., William Blair Investment Management LLC, Goldman Sachs Group Inc., Cowen Prime Services LLC, New York State Common Retirement Fund, Kornitzer Capital Management Inc. KS, and Bank of New York Mellon Corp. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff.
View insider buying and selling activity for GenMark Diagnostics
.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $15.10.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $1.07 billion and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is www.genmarkdx.com.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.